Commentary: New Topical Approaches Hit the Spots (and the Itch) for AD, October 2022September 27, 2022Atopic Dermatitis
Commentary: Something for Everyone in AD Treatment, September 2022September 21, 2022Atopic Dermatitis
Dermatology NewsTralokinumab earns EU recommendation to expand age range for atopic dermatitis to include adolescentsSeptember 20, 2022Atopic DermatitisPediatrics
Meta-analysis demonstrates potential of probiotics in reducing atopic dermatitis disease severitySeptember 19, 2022Atopic Dermatitis
Real-world characteristics of patients with moderate-to-severe atopic dermatitis receiving dupilumabSeptember 19, 2022Atopic Dermatitis
Pediatric atopic dermatitis and neuropsychiatric disorders: What is the link?September 19, 2022Atopic Dermatitis
Early initiation of emollient reduces risk for atopic dermatitis in high risk infantsSeptember 19, 2022Atopic Dermatitis
Moderate-to-severe atopic dermatitis: Astegolimab fails to reduce disease severity in phase 2 trialSeptember 19, 2022Atopic Dermatitis
EHA cream shows promise in children with mild-to-moderate atopic dermatitisSeptember 19, 2022Atopic Dermatitis
Rapid itch reduction with ruxolitinib in mild-to-moderate atopic dermatitisSeptember 19, 2022Atopic Dermatitis
Brepocitinib shows potential against mild-to-moderate atopic dermatitis in phase 2 trialSeptember 19, 2022Atopic Dermatitis
Meta-analysis finds no increased VTE risk in AD patients receiving JAK inhibitorsSeptember 19, 2022Atopic Dermatitis
Dupilumab shows good drug survival in moderate-to-severe atopic dermatitisSeptember 19, 2022Atopic Dermatitis
Optimizing Narrowband UVB Phototherapy: Is It More Challenging for Your Older Patients?September 14, 2022Contact DermatitisAtopic DermatitisPsoriasis
Dermatology NewsRoflumilast foam effectively eases seborrheic dermatitisSeptember 13, 2022Medical DermatologyAtopic Dermatitis
